IL247436A0 - Compositions and methods for the treatment of her2/neu over-expressing tumors - Google Patents

Compositions and methods for the treatment of her2/neu over-expressing tumors

Info

Publication number
IL247436A0
IL247436A0 IL247436A IL24743616A IL247436A0 IL 247436 A0 IL247436 A0 IL 247436A0 IL 247436 A IL247436 A IL 247436A IL 24743616 A IL24743616 A IL 24743616A IL 247436 A0 IL247436 A0 IL 247436A0
Authority
IL
Israel
Prior art keywords
her2
compositions
treatment
methods
expressing tumors
Prior art date
Application number
IL247436A
Other languages
Hebrew (he)
Original Assignee
Univ Pennsylvania
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by Univ Pennsylvania, Advaxis Inc filed Critical Univ Pennsylvania
Publication of IL247436A0 publication Critical patent/IL247436A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL247436A 2014-02-25 2016-08-23 Compositions and methods for the treatment of her2/neu over-expressing tumors IL247436A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (1)

Publication Number Publication Date
IL247436A0 true IL247436A0 (en) 2016-11-30

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247436A IL247436A0 (en) 2014-02-25 2016-08-23 Compositions and methods for the treatment of her2/neu over-expressing tumors

Country Status (13)

Country Link
EP (1) EP3110942A4 (en)
JP (1) JP2017507943A (en)
KR (2) KR20240038103A (en)
CN (1) CN106661538A (en)
AU (1) AU2015223136A1 (en)
BR (1) BR112016019534A2 (en)
CA (1) CA2940646A1 (en)
IL (1) IL247436A0 (en)
MX (1) MX2016011114A (en)
NZ (1) NZ723750A (en)
RU (1) RU2016137834A (en)
SG (1) SG11201607036XA (en)
WO (1) WO2015130810A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CN103687611A (en) 2011-03-11 2014-03-26 阿德瓦希斯公司 Listeria-based adjuvants
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
JP2017511796A (en) 2014-02-18 2017-04-27 アドバクシス， インコーポレイテッド Biomarkers for multitargeted immunotherapy
CN106413745A (en) * 2014-03-05 2017-02-15 阿德瓦希斯公司 Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
KR102359691B1 (en) 2014-04-24 2022-02-10 어드박시스, 인크. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
CN108601731A (en) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 Discriminating, manufacture and the use of neoantigen
MX2019005685A (en) 2016-11-30 2019-09-04 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof.
CA3075849A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
KR20200087143A (en) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 Identification of new antigens using hot spots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
AU2015223136A1 (en) 2016-09-22
SG11201607036XA (en) 2016-09-29
RU2016137834A (en) 2018-03-29
KR20160122829A (en) 2016-10-24
EP3110942A4 (en) 2017-08-30
CA2940646A1 (en) 2015-09-03
MX2016011114A (en) 2017-02-20
BR112016019534A2 (en) 2017-10-24
CN106661538A (en) 2017-05-10
EP3110942A2 (en) 2017-01-04
WO2015130810A2 (en) 2015-09-03
JP2017507943A (en) 2017-03-23
NZ723750A (en) 2024-02-23
WO2015130810A3 (en) 2016-01-28
KR20240038103A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
IL272572B (en) Antibody compositions for tumor treatment
IL246680A0 (en) Compounds and compositions for treating her2 positive tumors
IL258955A (en) Compositions and methods for treatment of cancer
IL247436A0 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
RS61536B1 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
EP3134436A4 (en) Treatment of h-ras-driven tumors
HK1247931A1 (en) Compositions and methods for diagnosis and treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3089992A4 (en) Compositions and methods for imaging cancer
ZA201808232B (en) Compositions and methods for the treatment of cancer
ZA201802831B (en) Composition for the treatment of igf-1r expressing cancer
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
ZA201707503B (en) Her2/neu immunogenic composition
IL255167A0 (en) Compositions for the treatment of cancer
ZA201707117B (en) Antibody compositions for tumor treatment
ZA201704589B (en) Compounds for the treatment of cancer
EP3365013A4 (en) Methods and related compositions for the treatment of cancer